Exosomal miRNAs Profile in Children's Nonalcoholic Fatty Liver Disease and the Correlation with Transaminase and Uric Acid.
Xuelian Zhou,Ke Huang,Junjun Jia,Yan Ni,Jinna Yuan,Xinyi Liang,Hu Lin,Wei Peng,Wei Wu,Guanping Dong,Junfen Fu
DOI: https://doi.org/10.1159/000506665
2020-01-01
Annals of Nutrition and Metabolism
Abstract:Introduction: Superior mesenteric artery syndrome (SMAS) is a relatively rare cause of chronic duodenal obstruction, owing to the compression of the third portion of the duodenum. Objectives: This retrospective study aims to discuss the efficacy of enteral nutrition (EN) therapy in nutritional status and symptom improvement at a short-term follow-up for SMAS patients. Methods: We retrospectively analyzed clinical data of patients diagnosed as SMAS and treated with EN from September 2012 to January 2019. Results: Twenty-six patients were included (16 women; mean age 24.96 +/- 11.77 years), none was excluded, and one was lost to follow-up. The patients' mean body weight was 40.94 +/- 10.16 kg, mean weight loss 11.73 +/- 7.58 kg, and mean body mass index (BMI) 14.82 +/- 2.52 kg/m(2). The mean duration of EN therapy was 10.10 +/- 4.66 months. Serum level of nutritional indicators, BMI and body weight increased after EN therapy. During a median follow-up of 24 months (9-44) after EN therapy, the mean symptom score decreased from 24.28 +/- 9.57 to 8.06 +/- 8.29 (p < 0.0001), and 65% of patients' symptoms resolved and 15% of patients' symptoms improved. In total, 16 complications occurred, including tube blockage, peristomal wound infections, peristomal leakage, granulomas, and nasopharyngeal pain. Conclusion: EN therapy may be an effective option for SMAS patients. While it might not remove all symptoms, it can improve the nutritional status to support subsequent treatments.